Skip to main content
. 2021 Aug 4;12(19):5864–5873. doi: 10.7150/jca.61068

Table 2.

Clinical and pathologic characteristics of patients with BC stratified by AFR in the whole cohort

Characteristics AFR P value
≤12.21 >12.21
Number of patients, n (%) 86 (24.0) 272 (76.0)
Age (year), n (%) <0.001*
≤65 18 (20.9) 131 (48.2)
>65 68 (79.1) 141 (51.8)
Gender, n (%) 0.183
Male 61 (70.9) 212 (77.9)
Female 25 (29.1) 60 (22.1)
BMI category, n (%) 0.251
Normal 40 (46.5) 142 (52.2)
Thin 5 (5.8) 5 (1.8)
Overweight 34 (39.5) 105 (38.6)
Obesity 7 (8.1) 20 (7.4)
Diabetes, n (%) 0.412
No 70 (81.4) 210 (77.2)
Yes 16 (18.6) 62 (22.8)
Smoking status, n (%) 0.480
Never 52 (60.5) 165 (60.7)
Ex-smoker 6 (7.0) 30 (11.0)
Current 28 (32.6) 77 (28.3)
T stage, n (%) 0.019*
Ta 43 (50.0) 174 (64.0)
T1 27 (31.4) 77 (28.3)
T2 10 (11.6) 14 (5.1)
T3+T4 6 (7.0) 7 (2.6)
Tumor grade, n (%) 0.037*
Low 31 (36.0) 133 (48.9)
High 55 (64.0) 139 (51.1)
Concomitant CIS, n (%) 0.492
No 82 (95.3) 264 (97.1)
Yes 4 (4.7) 8 (2.9)
Tumor multifocality, n (%) 0.574
No 47 (54.7) 158 (58.1)
Yes 39 (45.3) 114 (41.9)
Operation, n (%) 0.006*
TURBT 75 (87.2) 260 (95.6)
RC 11 (12.8) 12 (4.4)
Chemotherapy immediately after operation, n (%) 0.007*
No 19 (22.1) 29 (10.7)
Yes 67 (77.9) 243 (89.3)
Glb (g/L), Median (IQR) 31.2 (8.0) 29.2 (5.8) <0.001*
CHOL (mg/dL), Median (IQR) 168.0 (44.0) 176.9 (52.3) 0.003*
HDL (mg/dL), Median (IQR) 42.5 (11.6) 42.5 (15.5) 0.282
LDL (mg/dL), Median (IQR) 96.7 (35.8) 104.4 (42.5) 0.002*
Hb (g/L), Mean ± SD 129.4 ± 21.3 141.8 ± 17.4 <0.001*
PLT (109/L), Mean ± SD 211.4 ± 64.4 211.2 ± 54.0 0.984

Note: *P value<0.05.

Abbreviations: BC: bladder cancer; AFR: albumin-to-fibrinogen ratio; BMI: body mass index; CIS: carcinoma in situ; TURBT: transurethral resection of bladder tumor; RC: radical cystectomy; Glb: globulin; CHOL: cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; Hb: hemoglobin; PLT: blood platelet.